Human Albumin Solutions in Cirrhosis liver - Hept.Comm. Feb.2026

### **Human Albumin Solutions (HAS):**

Human Albumin Solution (HAS) is a sterile, purified preparation of human serum albumin, a protein derived from plasma. Albumin plays a critical role in maintaining oncotic pressure (fluid balance in blood vessels) and transporting various substances, including hormones, drugs, and waste products. HAS is administered intravenously and is widely used in clinical settings, particularly in conditions involving fluid imbalance, hypovolemia, and liver disease.

### **Human Albumin Solutions in Liver Cirrhosis:**

Liver cirrhosis is a chronic liver disease characterized by scarring (fibrosis) of liver tissue and impaired liver function. Decompensated liver cirrhosis refers to the stage where complications such as ascites (fluid accumulation in the abdomen), hepatic encephalopathy (brain dysfunction due to liver failure), renal dysfunction, and gastrointestinal bleeding occur. HAS is used in the management of these complications due to its ability to restore oncotic pressure, improve circulatory function, and reduce inflammation.

### **Evidence of Human Albumin Use in Cirrhosis:**

A systematic review and meta-analysis of 68 randomized controlled trials (RCTs) assessing the use of HAS in cirrhotic patients provides the following insights:

1. **Mortality Reduction:**

• HAS was associated with a statistically significant reduction in overall mortality compared to alternatives.
• The pooled random effect odds ratio (OR) for mortality was 0.769 (95% CI: 0.652–0.908, p=0.0019), indicating a 23.1% reduction in the odds of death.
• However, this mortality benefit was primarily observed in smaller trials with fewer than 100 participants.

2. **Reduction in Renal Dysfunction:**

• HAS was shown to reduce the odds of renal dysfunction, a common complication of liver cirrhosis, particularly in conditions like hepatorenal syndrome (HRS).

3. **Reduction in Recurrence of Ascites:**

• HAS reduced the risk of recurrent ascites, which is a frequent and challenging complication in cirrhotic patients.

4. **Other Complications:**

• HAS showed some benefit in reducing the risk of paracentesis-induced circulatory dysfunction (a complication of large-volume paracentesis, a procedure to remove ascitic fluid).
• Limited evidence suggested potential benefits in reducing bacterial infections, hepatic encephalopathy, and portal hypertensive bleeding, but these findings were less consistent.

### **Meta-Analysis Summary:**

• **Strengths:**
• The meta-analysis demonstrated that HAS has a positive impact on key outcomes, including mortality and complications like renal dysfunction and ascites.
• It supports the clinical use of HAS in managing decompensated liver cirrhosis.

• **Limitations:**
• The majority of the included RCTs were of small size and low quality, which raises concerns about the reliability of the findings.
• Only four of the 68 RCTs were evaluated as having a low risk of bias.
• The mortality benefit was primarily observed in small trials, suggesting the need for larger, high-quality trials to confirm the findings.

• **Conclusions:**
• While HAS appears to provide clinical benefits in cirrhotic patients, the evidence is not yet robust enough to make definitive recommendations.
• Future research should focus on conducting large, well-designed RCTs to better understand the effectiveness and safety of HAS in this population.

### **Current Clinical Use of HAS in Liver Cirrhosis:**

Based on existing evidence, HAS is recommended in specific scenarios for cirrhotic patients:

• **Large-Volume Paracentesis:** To prevent paracentesis-induced circulatory dysfunction.
• **Hepatorenal Syndrome (HRS):** In combination with vasoconstrictors to improve renal function.
• **Spontaneous Bacterial Peritonitis (SBP):** To reduce renal impairment and improve survival.

### **Future Directions:**

The systematic review highlights the need for high-quality research to clarify the role of HAS in liver cirrhosis. Future studies should aim to:

• Evaluate HAS in larger, multicenter RCTs with rigorous methodology.
• Investigate optimal dosing, timing, and duration of HAS therapy.
• Compare HAS with alternative therapies or combinations of therapies to determine the most effective approach.